Radius Health Strikes License Deal

Radius Health, a biopharmaceutical company, said Thursday it has entered into a license and development agreement with Teijin Limited for the commercialization in Japan of its abaloparatide injection for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Teijin is developing the drug in Japan under an agreement with Ipsen Pharma and has launched a phase 3 trial. The collaboration agreement provides Teijin with the right to manufacture abaloparatide in Japan, as well as the right to reference Radius’ regulatory data and intellectual property to support its marketing application in Japan.
Radius said it will receive unspecified upfront and milestone payments and royalties for the rights granted to Teijin.

Leave a Comment